Michael Gwarisa Zimbabwe is set to significantly expand access to Lenacapavir, the long-acting injectable HIV prevention drug, after securing additional financial support from the Global Fund through the United States Department of State, a development expected to strengthen HIV prevention efforts among high-risk populations. The new support will see an additional 43,000 doses added to